Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression.
about
Pathogenetic and Therapeutic Applications of Tumor Necrosis Factor-α (TNF-α) in Major Depressive Disorder: A Systematic ReviewThe Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific TreatmentsEvidence for the role of corticotropin-releasing factor in major depressive disorderInflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant usersMalaise, melancholia and madness: the evolutionary legacy of an inflammatory biasInflammation, obesity, and metabolic syndrome in depression: analysis of the 2009-2010 National Health and Nutrition Examination Survey (NHANES)Hepatocyte nuclear factor 4 alpha is a key factor related to depression and physiological homeostasis in the mouse brain.Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation.Transcriptomics in Interferon-α-Treated Patients Identifies Inflammation-, Neuroplasticity- and Oxidative Stress-Related Signatures as Predictors and Correlates of Depression.Neurotherapeutic implications of brain-immune interactions.Mind and body: how the health of the body impacts on neuropsychiatry.Genetic Contributions of Inflammation to Depression.The biology of depression in cancer and the relationship between depression and cancer progression.The role of inflammation in depression: from evolutionary imperative to modern treatment targetTherapeutic Implications of Brain-Immune Interactions: Treatment in Translation.Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder.
P2860
Q26749017-40E6B4B4-8F1E-4E3D-9A32-AF61583A1B26Q26783012-4E08B4B5-870D-4146-ACDB-E44EC545AEAFQ26798878-B3C4C323-92A9-49D7-97CA-09119422FDFFQ33620656-8C46D02F-70B9-42D0-B044-A588751D22B1Q34342600-E1C2DD4B-2ACD-4755-BF0C-57018431D234Q35023431-1C388039-5522-45C1-80AD-E25F6F35796CQ35182078-6BFBCEAF-42D8-4B42-8F1A-F8D2FC7EEA78Q35744195-D3ECFCFD-4986-4450-B143-F65FFB6AFD68Q37171783-1E978D68-EB65-4CBA-B90D-0C7741D7AB63Q37379484-3703BD11-1DEE-4B90-8CE8-DA771D5C0B20Q37399776-57BFDC5F-26A7-447C-9859-4F2BD9E54CCDQ37483043-35017B42-40A2-4688-9228-4BFE5B13E69DQ38203302-F4946FBE-7B70-4711-A0D8-BCBE288C7078Q38681725-77A8E24D-9AFE-4EBD-B240-5D779586252EQ38828405-B6DCD0CB-B189-4274-BF7F-81FD99B71257Q41707195-6C128EBF-814A-47BC-9134-EEBE7E9E0B5A
P2860
Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Transcriptional signatures rel ...... reatment-resistant depression.
@en
type
label
Transcriptional signatures rel ...... reatment-resistant depression.
@en
prefLabel
Transcriptional signatures rel ...... reatment-resistant depression.
@en
P2093
P2860
P50
P1476
Transcriptional signatures rel ...... reatment-resistant depression.
@en
P2093
Andrew H Miller
Charles L Raison
Elisabeth B Binder
Jennifer C Felger
P2860
P304
P356
10.1016/J.BBI.2013.04.004
P577
2013-04-25T00:00:00Z